Equity Overview
Price & Market Data
Price: $5.47
Daily Change: +$0.245 / 4.48%
Range: $5.20 - $5.55
Market Cap: $266,935,440
Volume: 838,846
Performance Metrics
1 Week: 12.78%
1 Month: 9.40%
3 Months: 4.19%
6 Months: -16.49%
1 Year: -25.68%
YTD: -1.80%
Company Details
Employees: 136
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, engineered cell therapy that is in a Phase 1/2a clinical trialfor recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.